Abstract 157P
Background
Gastric cancer (GC) is among the most common malignancy worldwide. The UICC/AJCC TNM classification is the most commonly used classification system. For adequate N staging at least 15 lymph nodes should be retrieved. In some countries, this amount of lymph nodes is not met, which can lead to understaging. The phenomenon of stage migration is caused by an insufficient number of lymph nodes examined. In order to reduce stage migration, some investigators have proposed using the metastatic lymph node ratio (LNR), namely the ratio between positive lymph nodes compared with the total number of lymph nodes examined, as a new prognostic indicator for gastric cancer.
Methods
Total 116 patients who underwent upfront D2 gastrectomy between 2012 to 2017 were included. LNR has classified into 4 groups: LNR0; 0, LNR1; >0-0.13; LNR2; 0.14-0.40 and LNR3; 0.41-1. We have used Kaplan-Meier method to calculate survival rates and log rank test to compare survival curves between groups.
Results
Males (58.6%) were more common than females (41.4%). Mean age at presentation was 56.12 years. Most common mode of presentation was pain abdomen (53.8%). Most common location of tumor was distal part (81%). Most commonly done procedure was distal radical gastrectomy (56.9%) followed by subtotal gastrectomy (32.8%). Median number of lymph nodes isolated was 14. 54 patients received adjuvant chemotherapy while 32 patients adjuvant chemoradiation. At a median followup of 14 months (range, 2–78 months), overall 5-year survival was 23.75%. (Median survival: 24 months). The 5-year survival for Stages I–III was 100%, 26.25%, and 11.25%, respectively (P < 0.001). In the univariate analysis; sex (p < 0.05), tumor grade (p < 0.001), T stage (p < 0.001), N stage (p < 0.001), TNM stage (p < 0.001), and LNR (p < 0.001) were statistically significant. The multivariate analysis showed that tumor grade, T stage, N stage, TNM stage and LNR still had statistical significance. In subgroup analysis of patients with less than 15 obtained lymph nodes, LNR was still a significant predictor of survival.
Conclusions
LNR can estimate prognosis of patients who undergo D2 gastrectomy, regardless of the number of lymph nodes examined. Thus LNR may become a new indicator to evaluate prognosis after D2 gastrectomy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
117P - Short-term and long-term outcomes of hepatectomy combined with intraoperative radiofrequency ablation for multiple colorectal liver metastases: A propensity score matching study
Presenter: Wenbai Huang
Session: Poster display session
Resources:
Abstract
119P - The impacts of dose-time-fractionation schedules on pathological complete response rate (pCR) and local recurrence (LR)
Presenter: Fu Jin
Session: Poster display session
Resources:
Abstract
120P - Platelet to lymphocyte ratio is associated with tumour localization and outcomes in patients with metastatic colorectal cancer
Presenter: Ahmet Bilici
Session: Poster display session
Resources:
Abstract
121P - Meta-analysis of three-dimensional versus two-dimensional laparoscopic surgery for rectal cancer
Presenter: Laiyuan Li
Session: Poster display session
Resources:
Abstract
127P - Outcomes based on albumin‐bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
Presenter: Stephen Chan
Session: Poster display session
Resources:
Abstract
128P - Tislelizumab in combination with chemotherapy for Chinese patients (Pts) with gastric/gastroesophageal junction cancer (GC/GEJC) or esophageal squamous cell carcinoma (ESCC)
Presenter: Yuxian Bai
Session: Poster display session
Resources:
Abstract
129P - Monitoring patient-specific mutation in ctDNA and CTC for tumour response evaluation after neoadjuvant chemotherapy in advanced gastric adenocarcinoma (NCT03425058)
Presenter: Tao Fu
Session: Poster display session
Resources:
Abstract
130P - Development of a liver cancer risk prediction model for the general population in china: A potential tool for screening
Presenter: Xiaoshuang Feng
Session: Poster display session
Resources:
Abstract
131P - Cabozantinib in Asian patients with hepatocellular carcinoma and other solid tumours: Population pharmacokinetics analysis
Presenter: Chih-Hung Hsu
Session: Poster display session
Resources:
Abstract
132P - Liposomal irinotecan (nal-IRI) plus 5-fluorouracil/levoleucovorin (5 FU/LV) vs 5-FU/LV in Japanese patients (pts) with gemcitabine-refractory metastatic pancreatic cancer (mPAC)
Presenter: Tatsuya Ioka
Session: Poster display session
Resources:
Abstract